Published in Drug Week, November 26th, 2004
These data were presented at the annual scientific meeting of the American College of Rheumatology (ACR) in San Antonio, Texas.
PAH, a life-threatening disease is a serious complication of connective tissue diseases like scleroderma (Ssc) and causes marked reduction in a patient's ability to function and overall survival. In PAH associated with scleroderma (PAH-Ssc), before the approval of PAH treatments, the median survival of patients has been reported...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2004-11-26)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.